Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma

Asociación de Oncología Médica del Hospital de Cruces

Status and phase

Completed

Phase 2

Conditions

Pancreatic Carcinoma Metastatic

Treatments

Drug: Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4

Drug: Gemcitabine 1000 weeks 1,2,3/4

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02391662

BIBABRAX

2014-003596-27 (EudraCT Number)

Details and patient eligibility

About

Cancer incidence is increasing with age and the likelihood of elderly suffering from cancer is 1:3. Although many clinical trials include elderly patients, no results for this subgroup of patients are available. Since there is no specific recommendations for treatment of elderly patients with pancreatic cancer, treatment with gemcitabine alone is the treatment of choice for these patients.

Single-agent gemcitabine is the current standard of care, but the addition of cytotoxic and targeted agents to gemcitabine has almost invariably provided no significant survival improvement.

Results obtained recently in the MPACT phase III clinical trial in patients with pancreatic cancer treated with nab-paclitaxel combined with gemcitabine have shown improvement in overall survival, but due to in this clinical trial was included patients between 27 and 88 years, it is considered necessary to conduct a specific study for patients over 70 years.

The aim of this study is to investigate whether the clinical benefit of nab-paclitaxel associated with gemcitabine can be extended to elderly patients with pancreatic cancer.

Enrollment

80 patients

Sex

All

Ages

70+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically or cytologically-confirmed pancreatic adenocarcinoma
Stage IV disease (metastatic only)
No prior systemic therapy for their diagnosis (except in adjuvant setting > six months previously)
ECOG performance status of 0-1
Age >=70 years.
Evidence of either or both of the following:
- RECIST-defined measurable disease (lesions that can be accurately measured in at least one dimension with the longest diameter >= 20mm using conventional techniques or >= 10 mm with spiral CT scan)
- An elevated serum CA19-9 at baseline ( >= 2X ULN)
Female patients must be either surgically sterile or postmenopausal.
Male patients must be surgically sterile or must agree to use a condom during sex with women who may become pregnant while receiving the study drug and for 6 months after receiving the last dose.
Adequate bone marrow function:
- ANC >= 1500/uL
- platelet count >= 100,000/uL
- hemoglobin >= 9.0 g/dL
Adequate hepatic function:
- Total bilirubin <= 1.5 X ULN
- AST (SGOT) <= 2.5 X ULN
- ALT (SGPT) <= 2.5 X ULN
Adequate renal function as determined by either:
- Serum creatinine <= 1.5 X ULN
- Calculated or measured creatinine clearance >= 40 mL/min (for calculated creatinine clearance, Cockroft-Gault equation will be used).
Ability to understand the nature of this study protocol and give written informed consent
Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

Any prior systemic or investigational therapy for metastatic pancreatic cancer.
Inability to comply with study and/or follow-up procedures.
History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study.
Presence of central nervous system or brain metastases.
Life expectancy < 12 weeks.
Pregnancy (positive pregnancy test) or lactation.
Prior malignancy except for adequately treated basal cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other form of cancer from which the patient has been disease-free for 5 years.
Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.
Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.
Known, existing uncontrolled coagulopathy.
Pre-existing sensory neuropathy > grade 1.
Major surgery within 4 weeks of the start of study treatment, without complete recovery.
Concurrent/pre-existing use of anticoagulant treatment.